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OBJECTIVE — The purpose of this study was to determine the prevalence of and risk factors
for diabetic neuropathy in a Canadian First Nation population.
RESEARCH DESIGN AND METHODS — This was a community-based screening
study of 483 adults. Measures included glucose, A1C, cholesterol, triglycerides, homocysteine,
hypertension, waist circumference, height, weight, and foot examinations. Neuropathy was
deﬁned as loss of protective sensation determined through application of a 10-g monoﬁlament.
RESULTS — Twenty-two percent of participants had a previous diagnosis of diabetes, and
14% had new diabetes or impaired fasting glucose (IFG). The prevalence of neuropathy in-
creasedbyglucoselevel:5%amongthosewithnormalglucoselevels,8%amongthosewithnew
IFG and diabetes, and 15% among those with established diabetes (P  0.01). Those with
neuropathy were more likely to have foot deformities (P  0.01) and callus (P  0.001) than
those without neuropathy. Among those with dysglycemia (6.1 mmol/l), the mean number of
footproblemsforthosewithinsensatefeetwas3comparedwith0.3amongthosewithsensation
(P  0.001). In multivariate logistic regression female sex, low education, A1C, smoking, and
homocysteine were independently associated with neuropathy, after controls for age.
CONCLUSIONS — Neuropathy prevalence is high, given the young age of our participants
(mean40years)andwaspresentamongthosewithundiagnoseddiabetes.Thehighnumberand
type of foot problems places this population at increased risk for ulceration; the low level of foot
care in the community increases the risk. Homocysteine is a risk factor that may be related to
lifestyle and requires further investigation.
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D
iabetes-related foot complications
are an increasingly common yet
understudied problem (1) and
include conditions such as neuropathy,
foot deformities, ulcers, and lower-
extremity amputation. The impact of
diabetes-related foot complications on
quality of life and health care costs is
signiﬁcant, especially for ulcers and
amputation (2–4). The lifetime risk for
foot ulceration among those with diabe-
tes is 15% (5,6), and foot ulceration pre-
cedes amputation in 80% of patients (5).
The major risk factors for diabetic foot
ulceration are peripheral neuropathy, pe-
ripheral vascular disease, and previous
foot ulcer (6). Of these, the most impor-
tant contributory factor for foot ulcer-
ation is peripheral neuropathy; when
neuropathy is absent, ulceration is rare
(5,7). It is estimated that 80% of foot ul-
cers may be prevented through early de-
tection (5). Screening for neuropathy has
therefore been identiﬁed as an effective
strategy in the prevention process (8).
Thepurposeofthisresearchwastodeter-
mine the prevalence and determinants of
diabetic neuropathy in a Canadian First
Nationcommunitythathasasigniﬁcantly
greater rate of diabetes-related amputa-
tion than that for the general population
(9).
Limited information exists on diabe-
tes foot complications in Canadian First
Nation populations. Depending on case
deﬁnition, estimates of neuropathy range
from 12% among a pediatric population
to 46% among adults (9–12). Hanley et
al. (10) reported the prevalence of neu-
ropathy to be 46% among adult members
of the Sandy Lake First Nation (northern
Ontario), with neuropathy being deﬁned
as a score of 2 on a modiﬁed Michigan
Neuropathy Screening Instrument. Reid
et al. (11) performed foot examinations,
interviews, and chart reviews on a sample
(139 of 322) of individuals with diabetes
in one northern Manitoba First Nation
community and found that 82% had
some form of diabetes-related foot prob-
lem. The average number of foot prob-
lems per individual was three.
Neuropathy was found among 24% of
participants, past or present foot ulcer in
15%, and 3% had had an amputation.
Chuback et al. (12) completed chart re-
views, interviews, and examinations on
110 Aboriginal attendees at an urban pe-
diatric diabetes clinic in Manitoba and
foundahighprevalenceoffootabnormal-
ities (age range of participants was 12–17
years). Neuropathic symptoms (numb-
ness, aching, and tingling) were found in
12% of participants. These results are
especially disturbing, considering the
short duration of diabetes in this pediat-
ric population.
The study community reported in
this article belongs to a tribal council for
which the rate of diabetes-related ampu-
tation (6.2 per 1,000) is twice as great as
that for other First Nations people in the
province (3.1 per 1,000) and 30 times
greaterthantheratefornon–FirstNations
people in the province (0.19 per 1,000)
(9). Thus, diabetes-related foot problems
are emerging as a serious complication of
diabetes among First Nations people of
Canada. We undertook a screening study
in a community with a high rate of ampu-
tationtodeterminetheburdenofneurop-
athy and to initiate secondary prevention
strategies.
The data for this article are from a
largerscreeningstudyfordiabetesanddi-
abetes complications conducted in 2003
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Community Health Services, University of Manitoba, Winnipeg, Manitoba, Can-
ada; and the
2Department of Public Health Services, University of Toronto, Toronto, Ontario, Canada.
Corresponding author: Sharon Bruce, brucesg@cc.umanitoba.ca.
Received 6 February 2008 and accepted 19 May 2008.
Published ahead of print at http://care.diabetesjournals.org on 28 May 2008. DOI: 10.2337/dc08-0278.
© 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Pathophysiology/Complications
ORIGINAL ARTICLE
DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1837among adult members of the Sandy Bay
First Nation. Sandy Bay First Nation is
located in Manitoba, Canada. The com-
munity is located about 200 km from
Winnipeg, the nearest major urban cen-
ter, and is accessible by road year-round.
The on-reserve population as of Decem-
ber 2001 was 2,968, of which 35% are
aged 18.
RESEARCH DESIGN AND
METHODS— As part of a larger
screening study for diabetes and diabetes
complications, all nonpregnant commu-
nity members aged 18 years were in-
vited to participate. A total of 483
community members participated, 36%
of all eligible adults (n  1,356). Full foot
examinations were completed for 467
participants.
Assessment of neuropathy
Neuropathy was deﬁned as the loss of
protective sensation determined through
application of the 10-g Semmes-
Weinstein monoﬁlament wire system.
Usingastandardizedquestionnaire,areg-
istered nurse ascertained experience of
foot pain, numbness, and tingling and
thencompletedafootexaminationforde-
formities, calluses, preulcers, ulcers, toe-
nail integrity, and amputation. After this
examination,thenurseappliedthemono-
ﬁlament to 10 sites on the foot. Partici-
pants who were unable to sense the
monoﬁlament on one or more sites were
deﬁned as insensate (13). Individuals
who had a previous foot ulcer (n  1) or
toeamputation(n3)wereplacedinthe
neuropathy category.
Risk factors for neuropathy
Glucose. Fasting samples were obtained
after an overnight 12-h fast. Glucose lev-
els were determined using the hexoki-
nase/glucose-6-phosphate dehydro-
genase assay. A1C determination was
based on the turbidimetric inhibition im-
munoassay for hemolyzed whole blood.
Participants with fasting glucose values
5.8mmol/lwererequestedtoreturnfor
a second sample, with the average of the
two samples being used in analysis. Dia-
betes was deﬁned as a fasting blood glu-
cose (FBG) 7.0 mmol/l. Impaired
fasting glucose (IFG) was deﬁned as FBG
of 6.1–6.9 mmol/l.
Lipids and amino acids. Total choles-
terol and triglycerides were determined
via enzymatic colorimetric methods
(CHOD-PAP and GPO-PAP; Boehringer
Mannheim, Mannheim, Germany). HDL
cholesterol was measured by a direct en-
zymaticmethod(BoehringerMannheim).
LDL was calculated via the following for-
mula but not on samples that had visible
chylomicrons or triglycerides 4.52
mmol/l:
LDL cholesterol  total cholesterol
 HDL cholesterol  (0.46
 triglycerides)
Apolipoproteins A and B were mea-
suredbytheBeckmanAPAandAPBtests,
respectively (Beckman Array Systems).
Quantitative determination of APA and
APB was completed by rate nephelome-
try. Total fasting homocysteine was de-
termined by high-performance liquid
chromatography with ﬂuorometric
detection.
Hypertension. Hypertension was de-
ﬁned systolic blood pressure 140
mmHg or diastolic blood pressure 90
mmHg or a previous diagnosis with
medications.
Anthropometric measures. Height,
weight, and waist and hip circumferences
were measured using standard tech-
niques (14).
Smoking. Currentandpastsmokingsta-
tus and number of cigarettes smoked per
day were determined using a standard-
ized questionnaire. Pack-years was calcu-
lated as number of packs per day (one
pack  20 cigarettes) multiplied by num-
ber of years smoked.
Demographic information. Standard
demographic information and diabetes
history were derived via questionnaire.
Analysis
Demographic, anthropomorphic, and
health risk characteristics were compared
by sex using 
2 tests for categorical vari-
ables and Kruskal-Wallis nonparametric
tests for continuous variables. Means 
SD are reported. 
2 tests for linear associ-
ation were used to assess differences in
foot problems by glycemic status. 
2 tests
were used to assess differences in foot
problems by protective sensation. Tests
were two-tailed with P  0.05 taken as
signiﬁcant. Multivariate logistic regres-
sion was used to estimate odds ratios for
thepresenceofneuropathywith95%CIs.
P values were two-tailed. Statistical anal-
yses were performed using SPSS (version
15; SPSS, Chicago, IL) and SAS (version
8; SAS Institute, Cary, NC).
RESULTS— Table 1 contains demo-
graphic and health risk information. Men
and women were equally represented.
The sample was representative of the eli-
gibleadultcommunitypopulationforage
and sex (Table 2). The level of employ-
ment is low for both sexes. Women were
signiﬁcantly more likely than men to re-
port having completed at least grade 9.
The majority of participants were current
smokers. Mean pack-years smoked was
about 8 for both sexes. Approximately
40% of men and women have hyperten-
sion.Althoughobesityisamajorproblem
in both men and women, the problem is
signiﬁcantly greater among women (15).
Oftheparticipants,29%haddiabetes;7%
(35of483)werenewdiagnoses,and22%
(105 of 483) had a previous diagnosis of
diabetes upon entry to the study. A fur-
ther 7% were found to have IFG. No sig-
niﬁcant differences in glycemic status
were found between men and women.
The mean age of those with dysglycemia
(44.51  11.97 years) was signiﬁcantly
greater than for those with normal glu-
cose values (34.01  10.77 years; P 
0.001), with dysglycemia being deﬁned
as FBG 6.1 mmol/l or previous diagno-
sis of diabetes.
Neuropathy
Neuropathic foot problems by glycemic
status are listed in Table 3. Overall, 34
participants (7%) had neuropathy. A sig-
niﬁcant progression in symptom occur-
rence is noted for all categories of
neuropathicproblemsbyglycemicstatus.
Neuropathy was present in those with
normalglucoselevels(5%),wasincreased
in those with newly discovered IFG or di-
abetes (8%), and was highest in those
with established diabetes (15%). Of the
participants, 34 (7%) reported numbness
and tingling and 38 (8%) reported foot
pain; 6 participants reported both.
Womenweremorelikelytoreportnumb-
ness and/or tingling (P  0.05). Of the
women,9%(21of240)hadinsensatefeet
compared with 6% (13 of 227) of men.
Signiﬁcant differences in age were found
between those with and without neurop-
athy. The mean age of those with neurop-
athy was 42.5  12.5 years, whereas the
mean age of those without neuropathy
was36.711.9years(P0.01).Among
the participants who reported a previous
diagnosis of diabetes, no signiﬁcant dif-
ferences in time since diagnosis were
found between those with and without
neuropathy and only 22% had previously
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provider before the screening study.
Participants with insensate feet were
signiﬁcantly more likely to have foot de-
formities (hallux valgus, hammer toes,
claw toes, and bony protuberances) (P 
0.01) and calluses (P  0.001) than were
thosewithsensation.Ofthosewithinsen-
sate feet, 18% (6 of 34) had an abnormal
foot shape versus 5% (20 of 427) of those
with sensation. Of those with insensate
feet, 41% (14 of 34) had plantar calluses
versus 12% (52 of 433) of those with sen-
sation. In addition, the mean number of
foot problems among dysglycemic partic-
ipants with insensate feet (3.15) was sig-
niﬁcantly greater than that among those
with sensation (0.27), with foot problems
deﬁned as pain, numbness, tingling, cal-
lus, nail pathological changes, foot defor-
mity, preulcer, current or past ulcer, and
amputation (P  0.001).
Usingmultivariatelogisticregression,
we sought to determine factors associated
with neuropathy (Table 4). Variables in-
cluded in the modeling process were
those that were signiﬁcantly associated
with neuropathy in bivariate 
2 testing.
These variables were age (P  0.01), ed-
ucation (P  0.01), employment status
(P0.01),hypertension(P0.05),A1C
(P  0.01), apolipoprotein A (P  0.05),
homocysteine(P0.05),andpack-years
smoked (P  0.01). Backwards stepwise
logistic regression was performed using
the preceding variables and sex. The ﬁnal
logistic regression model for presence
of neuropathy included sex (female
sex), education (completion of less than
grade 9), A1C, pack-years smoked, and
homocysteine.
The odds of having neuropathy were
2.7 times greater for women than for men
and 3 times greater among those who
completed less than grade 9 compared
with those who completed grade 9 or
higher. The odds of neuropathy increase
for each percent increase in A1C; the risk
for neuropathy is twice as great for some-
one with an A1C of 9 versus 6%. Neurop-
athy risk is three times greater for
someonewhosmoked30pack-yearsthan
for someone who smoked 10 pack-years.
Finally, the risk of neuropathy is twice as
greatforparticipantswithahomocysteine
level of 9 mol/l versus those with a level
of 13 mol/l (hyperhomocysteinemia de-
ﬁned as 12 mol/l) (16).
CONCLUSIONS — Of the partici-
pants with diabetes upon entry to the
study, 15% had neuropathy, a number
that is similar to recent estimates (17).
However, the mean age of our partici-
pants (40.7 years) is younger than that of
the comparison populations, and the
mean time since diabetes diagnosis is
comparatively short (8.75 years). The
prevalence of neuropathy increased sig-
niﬁcantly by glucose level, a ﬁnding that
is consistent with population-based stud-
ies(17)andcurrentunderstandingonthe
role of glycemic control in the develop-
ment and progression of neuropathy (7).
Of the individuals with new IFG or dia-
betes diagnoses, 8% had evidence of neu-
ropathy. Thus, complications were
developing at the time of diagnosis. The
Table 1—Characteristics and health risk proﬁle of the study population by sex
Variable Male Female P value
n 230 (48) 253 (52)
Age (years) 37.3  12.5 38.2  12.1 0.373
Age-group (years)
18–29 73 (32) 70 (28) 0.728
30–39 65 (28) 79 (31)
40–49 49 (21) 59 (23)
50 43 (19) 45 (18)
Education
Grade 9 or higher 89 (39) 131 (54) 0.01
Grade 9 138 (61) 111 (46)
Employment status
Employed 60 (26) 77 (31) 0.265
Not employed 169 (74) 170 (69)
Speak aboriginal language*
Yes 204 (89.5) 204 (83) 0.061
No 24 (10.5) 41 (17)
Current smoker
Yes 165 (73) 184 (75) 0.529
No 62 (27) 60 (25)
Pack-years smoked† 8.02  12.46 7.48  10.68 0.921
Hypertension‡
Yes 93 (41) 108 (44) 0.446
No 135 (59) 136 (56)
BMI (kg/m
2) 29.65  5.92 33.32  7.49 0.001
Large waist§
Yes 120 (53) 193 (81) 0.001
No 106 (47) 45 (19)
Glycemic status
Normoglycemic 150 (65) 161 (64) 0.444
Impaired fasting glucose 18 (8) 14 (5)
Diabetes  62 (27) 78 (31)
Data are n (%) or means  SD. *Local language is Saulteaux. †Number of packs per day (1 pack  20
cigarettes) 	 number of years smoked. ‡Systolic 140 mmHg or diastolic 90 mmHg. §Men 102 cm;
women 88 cm. Fasting glucose 6.1–6.9 mmol/l.  Fasting glucose 7.0 mmol/l or previous diagnosis.
Table 2—Eligible and study populations by sex and age-group
Eligible population* Study participants
Males Females Males Females
Age-group (years)
18–29 258 (35) 191 (31) 73 (32) 70 (28)
30–39 195 (27) 187 (30) 65 (28) 79 (31)
40–49 148 (20) 131 (21) 49 (21) 59 (23)
50–59 84 (11) 67 (11) 29 (13) 32 (13)
60 49 (7) 46 (7) 14 (6) 13 (5)
Total 734 622 230 253
Data are n (%). *Community members who met eligibility criteria (n  1,356).
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of foot problems may indicate that diabe-
tes complications occur more quickly
among this population and/or that diabe-
tes diagnoses are delayed. Participants
with neuropathy were, on average, older
than those without neuropathy. How-
ever, in multiple logistic modeling, glyce-
mic control was a stronger predictor of
neuropathy than age.
Individuals with neuropathy were
more likely to have other foot problems
compared with those without neuropa-
thy. The presence of these foot problems
increases the risk for foot ulceration
among those with insensate feet, because
of increased pressure loads and shearing
forces (7,8). Therefore, foot examinations
and treatment are a vital component of
ulcer and amputation prevention (8).
In multivariate logistic regression, fe-
male sex, low education level, A1C,
smoking, and homocysteine were inde-
pendently associated with neuropathy,
after controls for age. Completion of less
than grade 9 may be a marker of lower
socioeconomic status, which in turn may
be associated with poorer access to health
care services and self-care practices.
Smoking has been found to be associated
with neuropathy incidence among those
with type 1 diabetes (18). Homocysteine,
an amino acid that is produced from the
metabolismofmethionine(19),increased
risk for neuropathy independent of age,
sex, education level, A1C, and smoking.
Homocysteinehasbeenimplicatedincar-
dio- and cerebrovascular disease, primar-
ily through impairment of endothelial
functioning, leading to atherosclerosis
and thrombosis (16,19–22). However,
the etiological role of homocysteine in
cardio- and cerebrovascular disease has
not been established, so homocysteine
may be a marker for other factors or may
be related to other confounding factors
(16). Ambrosch et al. (20) found a rela-
tionship between homocysteine and neu-
ropathy among patients with type 2
diabetes. After addition of controls for
creatinine,vitaminsB12andB6,andfolate
(all confounders for homocysteine), ho-
mocysteine was signiﬁcantly associated
with neuropathy.
The study is subject to limitations.
First, the sample is relatively small. It is
possible that study participants are sys-
tematically different from those who did
not participate. However, the sample is
representative of the eligible community
population on demographic factors. Im-
portantly, we did not only screen the
“sickest” individuals in the community.
When data were collected for this study,
there were 275 community members
with diabetes; 105 participated in the
study. In addition, 10 individuals had am-
putations, and 15 individuals had end-
stage renal disease. Three individuals with
amputations participated in the study,
whereasnoneoftheindividualswithend-
stagerenaldiseaseparticipated.Theprev-
alence and pattern of neuropathy found
in our study are similar to those in other
population-based studies. Thus, we have
some conﬁdence that our sample is repre-
sentative of the eligible study population.
A second limitation is that we used
fasting glucose to identify glucose intoler-
ance, similar to other population-based
epidemiologicstudies.Hadwecompleted
2-h glucose tolerance tests, we probably
wouldhaveidentiﬁedmoreglucoseintol-
erance.Itispossiblethatsomeindividuals
we classiﬁed as normoglycemic may have
been dysglycemic. However, the relation-
ship between glucose control and neu-
ropathy was conﬁrmed in the logistic
regression analyses.
A third limitation is that our deﬁni-
tion of neuropathy may have high sensi-
tivitybutlowerspeciﬁcity.Useofthe10-g
monoﬁlament is a validated procedure
that has demonstrated ability to predict
riskforulcerationandamputation(8,23–
27). The protocol we followed has been
shown to be associated with large-ﬁber
neuropathy and increased risk for ulcer-
ation (27). Armstrong et al. (25) tested
sensitivity and speciﬁcity of the 10-g
monoﬁlament procedure and found that
speciﬁcityincreasedwithoutadecreasein
sensitivity up to four imperceptible sites.
Our use of one or more insensate sites
may have resulted in an overestimation of
neuropathy prevalence. However, as our
population is at high risk for ulceration
andamputation,wechoseaprotocolwith
high sensitivity. That our ﬁndings are
similar to those of recent population-
based studies provides conﬁdence in the
protocol.
Finally, we did not control for other
factors known to cause neuropathy (e.g.,
Table 3—Neuropathic foot problems by glycemic status
Normoglycemia
New IFG or
diabetes Previous diabetes P value*
Neuropathy†
Present 14 (5) 5 (8) 15 (15) 0.01
Absent 286 (95) 61 (92) 86 (85)
Pain
Present 18 (6) 6 (9) 14 (14) 0.05
Absent 282 (94) 60 (91) 87 (86)
Numbness, tingling
Present 14 (5) 8 (12) 12 (12) 0.01
Absent 286 (95) 58 (88) 88 (88)
Previous foot examination
Yes NA NA 22 (22) NA
No 78 (78)
Data are n (%). *
2 test for linear association. †Inability to sense 10-g monoﬁlament on 1 site/10. NA, not
applicable.
Table 4—Multivariate logistic regression analysis of factors associated with neuropathy

 (SEM) P value Exp (
) (95% CI)
Age 0.016 (0.02) 0.411 0.984 (0.946–1.023)
Sex
Male 1.00
Female 0.989 (0.428) 0.05 2.689 (1.163–6.220)
Education
Grade 9 1.00
Grade 9 1.118 (0.466) 0.05 0.327 (0.131–0.0814)
A1C 0.267 (0.089) 0.01 1.306 (1.097–1.556)
Homocysteine 0.151 (0.045) 0.01 1.163 (1.064–1.271)
Pack-years smoked 0.048 (0.013) 0.001 1.049 (1.023–1.077)
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thyroidism, and alcohol intake) (28) or
hyperhomocysteinemia (e.g., vitamin B6,
chronicalcoholintake,smoking,caffeine,
and certain medications) (16), so the re-
lationship between homocysteine and
neuropathy requires further investiga-
tion. However, although an inﬂuence of
dietary and lifestyle factors may be possi-
ble in this population, given the low so-
cioeconomic standing and self-reported
food insecurity, it is unlikely that they
completely explain the relationship be-
tween neuropathy and homocysteine.
The prevalence of neuropathy was great-
est among those with established diabe-
tes,intermediateamongthosewithnewly
discovered diabetes and IFG, and lowest
among those with normal glucose status.
If diet and lifestyle were the only factors
involved in occurrence of neuropathy, a
graded relationship with glycemic sta-
tus would not necessarily be present.
Nevertheless, lifestyle factors are impli-
cated in hyperhomocysteinemia, so fur-
ther investigation of this ﬁnding is
warranted.
TheburdenoffootproblemsinSandy
Bay is high, and access to foot care and
specialist services is limited. In a commu-
nity with a high amputation rate, only
22% of those with diabetes had ever re-
ceived a foot examination. We increased
community capacity to identify those at
greatest risk. We continue to work with
the community on secondary prevention
efforts.
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